Understanding the side effects of chronic silodosin administration via untargeted metabolomics approach

Background. - Precision medicine, which looks for high efficacy and low toxicity in therapies, has increased in popularity with omics technology. This work aims to discover novel and low-toxicity therapy options by examining the complex relationship between silodosin-induced side effects and the metabolomic profiles associated with its administration. Materials and methods. - The plasma samples of the control group and silodosin-treated rats were analyzed by LC-Q-TOF-MS/MS. Employing XCMS and MetaboAnalyst software, MS/MS data processed to detect compounds and investigate metabolic pathways. MATLAB 2019b was used for data categorization and multivariate analysis. A thorough comparison of METLIN and HMDB databases revealed 41 m/z values with significant differences between the drug-treated and control groups ( p < 0.01 and fold analysis > 1.5). Results. - According to multivariate data analysis, 17-,e-estradiol, taurocholic acid, Lkynurenine, N-formylkynurenine, D-glutamine, L-arginine, prostaglandin H2, prostaglandine G2, 15-keto-prostaglandin E2, calcidiol, thromboxane A2, 5'-methylthioadenosine, L-methionine and S-adenosylmethionine levels changed significantly compared to the control group. Differences in the metabolisms of glycerophospholipid, tyrosine, phenylalanine, arachidonic acid, cysteine and methionine, and biosynthesis of phenylalanine, tyrosine, and tryptophan, and aminoacyl-tRNA have been successfully demonstrated by metabolic pathway analysis. According to this study, vitamin D, D-glutamine, and L-arginine supplements can be recommended to prevent side effects such as fatigue, intraoperative floppy iris syndrome, blurred vision, and dizziness in the treatment of silodosin. Silodosin treatment negatively affected the immune system by affecting the kynurenine and tryptophan metabolism pathways. Conclusions. - The study is a guide for silodosin treatments that offer low side effects and high therapeutic effect within the scope of precision medicine. (c) 2024 Acade<acute accent>mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Journal

ANNALES PHARMACEUTIQUES FRANCAISES

Year

2024

Volume

82

Issue

6

Pages

1150-1162

ISSN

0003-4509

DOI

10.1016/j.pharma.2024.08.002

WoS UID

WOS:001344266000001